Levobupivacaine-d9 (hydrochloride)

Formulation: A solid

Formal Name: 1-butyl-d9-N-(2,6-dimethylphenyl)-(2S)-2-piperidinecarboxamide, monohydrochloride

Purity: ≥99% deuterated forms (d1-d9)

Formula Markup: C18H19D9N2O • HCl

Formula Weight: 333,9

Shelf life (days): 1095

Notes: Levobupivacaine-d9 is intended for use as an internal standard for the quantification of levobupivacaine (Item No. 31596) by GC- or LC-MS. Levobupivacaine is a sodium channel blocker and local anesthetic, as well as the levorotary stereoisomer of bupivacaine (Item No. 16618).{58122,58123,42580} It inhibits cardiac sodium channel currents (INa) by 57.8% in isolated guinea pig ventricular myocytes when used at a concentration of 10 μM.{58122} Levobupivacaine (10 μM) reduces the maximal rate of depolarization (Vmax) and action potential duration to 76.7 and 83.4% of controls, respectively, in isolated guinea pig papillary muscle.{58123} It induces a complete block of proprioception, motor function, and nociception in the hindleg of rats when administered at a dose of 7.7 mM by percutaneous injection into the sciatic nerve.{42580}

• Artikelnummer: CAY38904-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 38904-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung